The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Moab, I’m not sure what “distinction” you were trying to point out to EC and then you got a bit huffy when he told you he was quoting from the RNS.
If you want authors, try this research paper from Angle. I believe MDPI is a peer reviewed publication, but I am not 100% sure. I am sure you will tell me if I am incorrect.
https://angleplc.com/wp-content/uploads/2024/01/Molecular-Profiling-of-Circulating-Tumour-Cells-and-Circulating-Tumour-DNA_Wishart-et-al.-January-2024-1.pdf
PS what does this mean? “They [Illumina] may wish to continue to use their widget for screening purposes only.” I’ve not heard it called a “widget” before. Presumably you mean Illumina’s Next Generation Sequencing (NGS) system?
Touk - “In what way has the trial been better than we dared expect? Fantasists keep saying this but the trial results are no better than the rat trials and I have to believe that Avacta expected human trials to yield similar results.”
A question regarding the PDX model was asked in 2022, in the Investor Meet Final Results presentation in the Q&A (question 7). Basically, you can be guided by the rodent data but it is not definitive. So, it is entirely plausible that the clinical data is better than the company initially anticipated.
Question 7
Can you elaborate on the use of human tissue or cells (the PDX model) in the pre-clinical mice studies and explain how this makes the pre-clinical trials much more relevant to the current Phase 1 in-human trials?
Answer:
The patient derived xenograft uses patient tumour cells implanted into a mouse with a reduced immune system, so that the tumour cells are not rejected. These patient derived cells will have more diversity (heterogeneity) than more traditional immortalised cell lines, and often have a tumour architecture and molecular signature more like the original tumour. These cells therefore look more like an actual patient tumour and the PDX models are deemed to be best for translating data from mice to human. However, there are clear differences between rodents and humans. For example, circulating FAP levels are higher in rodents than in humans and so you cannot directly translate between the two species. You can, however, be guided by the data from these models.
https://www.investormeetcompany.com/meetings/final-results-21
T2GD, you haven’t provided any evidence to back up your claim - “What's been posted is accurate and fair for a lab to get accreditation it needs FDA approval to use the Parsortix machine for the 96% of all cancers groups that Parsortix is currently not approved to be used to test!”
You won’t be able to because it’s BS. Why do you obsessively post on here by the way?
What “crew” am I in Watching? I haven’t deramped AVCT, although I was disappointed at a placing (and the circumstances around it) at only 50p.
Just because I want to read posts and make my own mind up does not make me Eggy, Derek etc. Also when you get posts deleted it often ends up getting other posts removed in an indiscriminate “clean up” by LSE.
Absolutely GoSushi. Even if “all” AVA6000 achieved was chemo with limited side effects then that is one hell of an achievement. It would significantly improve the quality of patients lives and extend how long they can have on treatment, and potentially and crucially how long they live. If AVA6000 can go further than that and actually reduce tumours then we have something very, very special.
Negative at only a 50p placing that was badly managed and let the shorters in. But at least we are fully funded now so hopefully upwards & onwards.
It’s your nasty abusive posts which are the real negative on here. You’re binned, life’s too short to keep reading your unpleasant vitriol.
Hi Bella, you are correct in what you say regarding TR1 thresholds, HOWEVER the thresholds for “non-UK issuers” are 5%, 10%, 15% etc.
https://www.handbook.fca.org.uk/handbook/DTR/5/1.html
That is a fair point B2HS2L. The same could probably be said for Eliot Foster, who since November 2023, is full-time CEO of Levicept. I appreciate, that to hold a number of roles in different companies is not unusual, but Eliot must have a very full diary and be juggling a lot of commitments.
This is from EF’s LinkedIn page:
Chief Executive Officer
Levicept |
LEVICEPT LTD • Full-time
Nov 2023 - Present • 5 mos
Hybrid
Non Executive Chair
Tessellate BIO • Part-time
Sep 2023 - Present • 7 mos
Remote
Non Executive Director
Immatics
Sep 2021 - Present • 2 yrs 7 mos
Chairman Of The Board
AVACTA GROUP PLC • Part-time
May 2018 - Present • 5 yrs 11 mos
Cambridge, United Kingdom
I agree Pd195.
It is a bitter pill to swallow for LTH’s who have shouldered all the risk to then have to accept a poorly managed, heavily discounted placing at only 50p. New investors will be delighted at a bargain price and the shorters are crowing with glee and rubbing our nose in it further. Fecking TW.
Not quite so bad for existing investors if they can take “advantage” of these prices, but many of us may not have the funds available and are sitting on very substantial paper losses. AS’s credibility has taken a serious knock.
Cindercone, ref your 15:45 post, it hit the nail on the head for me. It is not a level playing field for investors and it stinks that some people have had inside information and profited at others expense. AVCT have handled it badly and the regulatory enforcement on clamping down on leaks etc seems toothless & virtually non-existent.
“The fury is not so much the raise, everyone knew it would come at some point, but how the SP was walked down for a fortnight and that certain investors have benefited at the expense of others. There is not just an air of incompetence in how this has been conducted, but impropriety, which not only erodes trust in Avacta but AIM as a market. People are sick of it.” (Cindercone)
Beinthelead, I agree McMuff summed it up perfectly. But this is the most closed minded, in denial board I have been on. No view point is tolerated unless it toes the party line. You are talking out of your ar*e if you think the TG board will put a positive spin on a placing at this current SP or lower.
Livedatasccount, they are valid questions you ask. An aggressive reply (DTW) and an attempt to shut the question down means that it is an uncomfortable question you have asked. At the very least we should have had some comms about the completion of C7.
Shame Starbright’s balanced and objective post has disappeared off the board.